Compare Bristol-Myers Squibb Co (BMY) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Innodata Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Innodata Inc trades at $67.32 (market cap $2.19B). The key difference: Bristol-Myers Squibb Co is far larger — about 53.1× Innodata Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| BMY | INOD | |
|---|---|---|
Market Cap | $116.30B | $2.19B |
Sector | Health | Technology |
52-Week High | $62.37 | $121.50 |
52-Week Low | $42.60 | $34.45 |
Enterprise Value | $152.24B | $2.08B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
INOD trades at $68.12, up 0.47% today but down 33% over the past month. The stock shows strong fundamentals with revenue growth to $252M in 2025 and net income of $32M, while beating EPS estimates in recent quarters. Technical indicators signal a bearish trend, with resistance at $69 and support at $67. Recent news highlights AI-driven growth and a new CFO appointment.
Outlook remains positive due to AI demand and raised guidance, but high valuation (P/E 59.89) and customer concentration pose risks. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
